TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+5.04%+3.27%+50.62%+105.43% 6.69TCr
+1.64%-2.89%+34.67%+80.49% 6.2TCr
-3.04%+0.33%-12.46%+369.83% 2.83TCr
+4.55%-0.08%+34.70%+17.28% 2.46TCr
+2.07%+0.12%+0.92%-13.21% 2.43TCr
+1.15%-1.17%+18.94%-21.92% 1.94TCr
-7.03%-9.16%+161.91%+303.00% 1.68TCr
+3.44%-1.68%-5.00%+541.17% 1.42TCr
+5.10%+6.45%-2.88%+863.09% 1.4TCr
Average +1.27%-3.94%+31.27%+249.46% 3TCr
Weighted average by Cap. +1.98%-2.84%+33.40%+173.86%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!